Pasireotide Versus Octreotide in Acromegaly: A Head-to-Head Superiority Study

Imagem de Miniatura
Arquivos
art_COLAO_Pasireotide_Versus_Octreotide_in_Acromegaly_A_Head_to_2014.PDF (349.99 KB)
Citações na Scopus
334
Tipo de produção
article
Data de publicação
2014
Editora
ENDOCRINE SOC
DOI
Indexadores
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Autores
COLAO, A.
FREDA, P.
GU, F.
SHEN, C. -C.
GADELHA, M.
FLESERIU, M.
LELY, A. J. van der
FARRALL, A. J.
RESENDIZ, K. Hermosillo
Autor de Grupo de pesquisa
Pasireotide C2305 Study Grp
Editores
Coordenadores
Organizadores
Citação
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, v.99, n.3, p.791-799, 2014
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Context: Biochemical control reduces morbidity and increases life expectancy in patients with acromegaly. With current medical therapies, including the gold standard octreotide long-acting-release (LAR), many patients do not achieve biochemical control. Objective: Our objective was to demonstrate the superiority of pasireotide LAR over octreotide LAR in medically naive patients with acromegaly. Design and Setting: We conducted a prospective, randomized, double-blind study at 84 sites in 27 countries. Patients: A total of 358 patients with medically naive acromegaly (GH > 5 mu g/L or GH nadir >= 1 mu g/L after an oral glucose tolerance test (OGTT) and IGF-1 above the upper limit of normal) were enrolled. Patients either had previous pituitary surgery but no medical treatment or were de novo with a visible pituitary adenoma on magnetic resonance imaging. Interventions: Patients received pasireotide LAR 40 mg/28 days (n = 176) or octreotide LAR 20 mg/28 days (n = 182) for 12 months. At months 3 and 7, titration to pasireotide LAR 60 mg or octreotide LAR 30 mg was permitted, but not mandatory, if GH >= 2.5 mu g/L and/or IGF-1 was above the upper limit of normal. Main Outcome Measure: The main outcome measure was the proportion of patients in each treatment arm with biochemical control (GH <2.5 mu g/L and normal IGF-1) at month 12. Results: Biochemical control was achieved by significantly more pasireotide LAR patients than octreotide LAR patients (31.3% vs 19.2%; P = .007; 35.8% vs 20.9% when including patients with IGF-1 below the lower normal limit). In pasireotide LAR and octreotide LAR patients, respectively, 38.6% and 23.6% (P = .002) achieved normal IGF-1, and 48.3% and 51.6% achieved GH <2.5 mu g/L. 31.0% of pasireotide LAR and 22.2% of octreotide LAR patients who did not achieve biochemical control did not receive the recommended dose increase. Hyperglycemia-related adverse events were more common with pasireotide LAR (57.3% vs 21.7%). Conclusions: Pasireotide LAR demonstrated superior efficacy over octreotide LAR and is a viable new treatment option for acromegaly.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/7909
Referências
  1. [Anonymous], DIABETES CARE S1, V33, pS62
  2. Arosio M, 2012, EUR J ENDOCRINOL, V167, P189, DOI 10.1530/EJE-12-0084
  3. Breitschaft A, 2014, DIABETES RES CLIN PR, V103, P458, DOI 10.1016/j.diabres.2013.12.011
  4. Bruns C, 2002, EUR J ENDOCRINOL, V146, P707, DOI 10.1530/eje.0.1460707
  5. Colao A, 2009, CLIN ENDOCRINOL, V70, P757, DOI 10.1111/j.1365-2265.2008.03441.x
  6. Cozzi R, 2003, J CLIN ENDOCR METAB, V88, P3090, DOI 10.1210/jc.2003-030110
  7. Dietrich H, 2012, EUR J ENDOCRINOL, V166, P821, DOI 10.1530/EJE-11-0773
  8. Fleseriu M, 2011, PITUITARY, V14, P184, DOI 10.1007/s11102-010-0282-z
  9. Flogstad AK, 1997, J CLIN ENDOCR METAB, V82, P23, DOI 10.1210/jc.82.1.23
  10. Giustina A, 2010, J CLIN ENDOCR METAB, V95, P3141, DOI 10.1210/jc.2009-2670
  11. Grasso LFS, 2012, CURR OPIN ENDOCRINOL, V19, P288, DOI 10.1097/MED.0b013e328354af67
  12. Henry RR, 2013, J CLIN ENDOCR METAB, V98, P3446, DOI 10.1210/jc.2013-1771
  13. Holdaway IM, 2008, EUR J ENDOCRINOL, V159, P89, DOI 10.1530/EJE-08-0267
  14. Hu K, 2009, 91 ANN M END SOC JUN
  15. Lancranjan I, 1996, METABOLISM, V45, P67, DOI 10.1016/S0026-0495(96)90087-6
  16. Lancranjan I, 1999, Pituitary, V1, P105
  17. Melmed S, 2009, J CLIN ENDOCR METAB, V94, P1509, DOI 10.1210/jc.2008-2421
  18. Melmed S, 2010, PITUITARY, V13, P18, DOI 10.1007/s11102-009-0191-1
  19. Mercado M, 2007, CLIN ENDOCRINOL, V66, P859, DOI 10.1111/j.1365-2265.2007.02825.x
  20. Murray RD, 2004, J CLIN INVEST, V114, P349, DOI 10.1172/jci200419933
  21. National Cancer Institute and National Institutes of Health, COMM TERM CRIT ADV E
  22. Nomikos P, 2005, EUR J ENDOCRINOL, V152, P379, DOI 10.1530/eje.1.01863
  23. Petersenn S, 2012, J CLIN PHARMACOL, V52, P1017, DOI 10.1177/0091270011408727
  24. Petersenn S, 2008, 90 ANN M END SOC JUN
  25. Petersenn S, 2010, J CLIN ENDOCR METAB, V95, P2781, DOI 10.1210/jc.2009-2272
  26. Pokrajac A, 2009, EUR J ENDOCRINOL, V160, P543, DOI 10.1530/EJE-08-0822
  27. Webb SM, 2002, CLIN ENDOCRINOL, V57, P251, DOI 10.1046/j.1365-2265.2002.01597.x

Coleções
Artigos e Materiais de Revistas Científicas - LIM/25
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - ODS/03